The introduction of an oral option is widely seen as a potential inflection point for obesity treatment, with experts noting it could broaden access and support wider uptake as the category continues to expand
Sublingual administration, which is not FDA approved, involves placing the medication under the tongue, allowing it to be absorbed directly into the bloodstream
[5, 6] It is considered the main redox buffer in human cells owing to its large amount of reducing equivalents, [7] and is an important enzyme cofactor that serves as a neuromodulator in the central nervous system
Remaining at a low dose may improve tolerability for some patients, but it may not provide adequate glucose control for others
Who Can Enter
Mazdutide represents another triple agonist combining GLP-1, glucagon, and GIP activity